Amylin Analogs and the Tolerability Question

August 14, 2026

Amylin analogs have moved from a long-dormant corner of metabolic pharmacology into one of the more active areas of obesity research, and cagrilintide is the compound most researchers encounter first. A review published in Pharmacological Research on 12 August 2026 by Sophia Fischer and Tito Borner of the University of Southern California takes stock of where the class stands. Its framing is worth noting: rather than ranking compounds by weight-loss magnitude, the authors organize the field around tolerability, and argue that the differences in how these molecules engage their receptors may explain why some produce nausea and vomiting more readily than others.

What amylin does

Amylin is a hormone released by pancreatic β-cells alongside insulin in response to a meal. The review summarizes its established physiology: it contributes to post-meal glucose regulation, slows the rate at which the stomach empties, suppresses glucagon secretion, and promotes satiation through actions in the central nervous system. That last effect is the one driving pharmaceutical interest, and it runs through a pathway separate from the incretin system that GLP-1 receptor agonists engage — which is the mechanistic rationale behind research designs that pair an amylin-pathway compound with a GLP-1-pathway compound rather than treating them as interchangeable.

Why the class is only now maturing

Native amylin is not a practical therapeutic molecule on its own. What changed, per the review, is peptide engineering: advances in lipidation and reversible albumin binding made it possible to build amylin-based agents with half-lives long enough for once-weekly administration in trial settings. The authors identify cagrilintide, eloralintide, petrelintide and NN1213 as the compounds defining the current landscape, and note that they are not variations on a single design — they differ meaningfully in both pharmacokinetic behavior and which receptors they engage.

Selective agonism versus dual receptor engagement

This is the review’s central technical distinction. The compounds in question span a range from relatively selective amylin receptor agonists to dual amylin/calcitonin receptor agonists — cagrilintide sits in the latter group, acting on both. The authors argue this is not a footnote in the pharmacology but potentially the variable that determines both how effective a compound is and how well it is tolerated, since calcitonin receptor engagement pulls in signaling that a more selective amylin agonist would not.

Exposure kinetics compound the picture. How quickly a compound reaches the relevant receptors, and how long it stays there, appears to shape the downstream response independently of which receptors it binds. Two molecules with similar receptor profiles but different exposure curves may therefore behave quite differently in practice.

Satiation or aversion

The most useful conceptual point in the paper concerns something that is easy to miss in trial data: reduced food intake is an outcome that two very different mechanisms can produce. It can reflect physiological satiation — the ordinary signal that a meal is sufficient — or it can reflect aversive signaling, where intake falls because the animal or participant feels unwell. Both show up as the same number on a chart.

The authors trace this distinction to specific neural territory, discussing how hindbrain and parabrachial circuitry, along with species differences in how these circuits are wired, may determine which of the two a given compound recruits. Separating weight-loss efficacy from gastrointestinal intolerance, they suggest, is a design problem that can be attacked at the level of receptor pharmacology rather than accepted as an unavoidable cost of the mechanism.

What this adds for someone working with these compounds

For researchers handling cagrilintide, this review is context rather than a new experimental result — it is a synthesis of the class, not a study of a single compound. Its practical value is in explaining why cagrilintide’s dual amylin/calcitonin profile is a meaningful characteristic to note in a research design rather than an incidental detail, and why comparisons across amylin analogs should account for receptor selectivity and exposure profile rather than treating the class as homogeneous.

Two limitations are worth stating plainly. This is a review of existing literature, not new data, and much of the mechanistic circuit work it draws on comes from animal models where species differences are themselves part of the open question. The authors also disclose that Borner receives research funding from Novo Nordisk, which develops cagrilintide, though they state that funding did not support this work. None of the above constitutes clinical guidance; the compounds discussed remain investigational and are described here strictly as they appear in the scientific literature.